Lantern Pharma Partners with New to The Street for AI-Driven Cancer Drug Development Visibility

National Media Partnership Launch

• 🤝 Lantern Pharma (NASDAQ: LTRN) is initiating a significant national media partnership with New to The Street.
• 🎯 The collaboration aims to highlight Lantern Pharma's advancements in AI-driven cancer drug development.

Partnership Inclusions

• 📺 The partnership includes a full year of national TV interview programming.
• 💰 Commercial campaigns will run across top finance channels.
• 🏙️ High-impact billboard exposure is planned for NYC's Financial District and Times Square.

Broadcast Details

• 📰 Lantern Pharma will be featured on New to The Street's syndicated broadcasts on Bloomberg Television and Fox Business Network.
• 👥 This is part of a strategy to engage both institutional investors and the general public.

Company Mission and AI Focus

• 🚀 CEO Panna Sharma states the partnership supports Lantern's mission to accelerate the discovery and development of life-saving oncology therapies.
• 💡 The company utilizes artificial intelligence and data-driven insights in its drug development process.
• 🔬 Lantern Pharma is bringing AI to the future of oncology.